Force­field Ther­a­peu­tics to start £35M Se­ries A in Oc­to­ber af­ter scoop­ing ex-No­var­tis ex­ec John Tsai as new CEO

For­mer No­var­tis chief med­ical of­fi­cer John Tsai is now a biotech CEO, and one of his first pri­or­i­ties at Lon­don, UK-based car­dio­vas­cu­lar biotech Force­field Ther­a­peu­tics will be to raise £35 mil­lion ($42 mil­lion) in a Se­ries A round.

“We’re plan­ning on kick­ing off the Se­ries A in the ear­ly part of Oc­to­ber… and we’re go­ing to give our­selves a win­dow of about four to six months to try to raise £35 mil­lion,” Tsai told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER